BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 18056190)

  • 1. Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome.
    Grövdal M; Khan R; Aggerholm A; Antunovic P; Astermark J; Bernell P; Engström LM; Kjeldsen L; Linder O; Nilsson L; Olsson A; Wallvik J; Tangen JM; Oberg G; Jacobsen SE; Hokland P; Porwit A; Hellström-Lindberg E
    Clin Cancer Res; 2007 Dec; 13(23):7107-12. PubMed ID: 18056190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
    Grövdal M; Karimi M; Khan R; Aggerholm A; Antunovic P; Astermark J; Bernell P; Engström LM; Kjeldsen L; Linder O; Nilsson L; Olsson A; Holm MS; Tangen JM; Wallvik J; Oberg G; Hokland P; Jacobsen SE; Porwit A; Hellström-Lindberg E
    Br J Haematol; 2010 Aug; 150(3):293-302. PubMed ID: 20497178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients.
    Aggerholm A; Holm MS; Guldberg P; Olesen LH; Hokland P
    Eur J Haematol; 2006 Jan; 76(1):23-32. PubMed ID: 16343268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypermethylation of the p15(INK4B) gene in acute leukemia and myelodysplastic syndromes.
    Chen H; Wu S
    Chin Med J (Engl); 2002 Jul; 115(7):987-90. PubMed ID: 12150726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative analysis of hypermethylation of cell cycle control and DNA-mismatch repair genes in low-density and CD34+ bone marrow cells from patients with myelodysplastic syndrome.
    Hofmann WK; Takeuchi S; Takeuchi N; Thiel E; Hoelzer D; Koeffler HP
    Leuk Res; 2006 Nov; 30(11):1347-53. PubMed ID: 16682076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [p15(INK4B) methylation on prognosis and response to decitabine in patients with MDS].
    Zhang Y; Song LX; Wu LY; Chang CK; Li X
    Zhonghua Xue Ye Xue Za Zhi; 2013 Mar; 34(3):237-41. PubMed ID: 23683424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation.
    Tien HF; Tang JH; Tsay W; Liu MC; Lee FY; Wang CH; Chen YC; Shen MC
    Br J Haematol; 2001 Jan; 112(1):148-54. PubMed ID: 11167795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylation status of the p15 and p16 genes in paediatric myelodysplastic syndrome and juvenile myelomonocytic leukaemia.
    Hasegawa D; Manabe A; Kubota T; Kawasaki H; Hirose I; Ohtsuka Y; Tsuruta T; Ebihara Y; Goto Y; Zhao XY; Sakashita K; Koike K; Isomura M; Kojima S; Hoshika A; Tsuji K; Nakahata T
    Br J Haematol; 2005 Mar; 128(6):805-12. PubMed ID: 15755284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Detection of methylation levels of multi-genes by real-time PCR in patients with myelodysplastic syndrome].
    Wang YC; DU X; Geng SX; Li YY; Weng JY; Lu ZS; Zhong LY; Deng CX; Lai PL; Huang X
    Zhonghua Xue Ye Xue Za Zhi; 2011 Apr; 32(4):254-8. PubMed ID: 21569709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
    Song LX; Xu L; Li X; Chang CK; Zhang Y; Wu LY; He Q; Zhang QX; Li X
    Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia.
    Christiansen DH; Andersen MK; Pedersen-Bjergaard J
    Leukemia; 2003 Sep; 17(9):1813-9. PubMed ID: 12970781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment.
    Daskalakis M; Nguyen TT; Nguyen C; Guldberg P; Köhler G; Wijermans P; Jones PA; Lübbert M
    Blood; 2002 Oct; 100(8):2957-64. PubMed ID: 12351408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
    Alhan C; Westers TM; van der Helm LH; Eeltink C; Huls G; Witte BI; Buchi F; Santini V; Ossenkoppele GJ; van de Loosdrecht AA
    Cytometry B Clin Cytom; 2014 May; 86(3):207-15. PubMed ID: 24474614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Beran M; Kantarjian H
    Semin Hematol; 1999 Oct; 36(4 Suppl 8):3-10. PubMed ID: 10622223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia.
    Chamseddine AN; Cabrero M; Wei Y; Ganan-Gomez I; Colla S; Takahashi K; Yang H; Bohannan ZS; Garcia-Manero G
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S67-73. PubMed ID: 27521329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
    Cortes J; Kantarjian H; Albitar M; Thomas D; Faderl S; Koller C; Garcia-Manero G; Giles F; Andreeff M; O'Brien S; Keating M; Estey E
    Cancer; 2003 Mar; 97(5):1234-41. PubMed ID: 12599230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease.
    Hast R; Hellström-Lindberg E; Ohm L; Björkholm M; Celsing F; Dahl IM; Dybedal I; Gahrton G; Lindberg G; Lerner R; Linder O; Löfvenberg E; Nilsson-Ehle H; Paul C; Samuelsson J; Tangen JM; Tidefelt U; Turesson I; Wahlin A; Wallvik J; Winquist I; Oberg G; Bernell P
    Leukemia; 2003 Sep; 17(9):1827-33. PubMed ID: 12970783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.
    Radujkovic A; Dietrich S; Andrulis M; Benner A; Longerich T; Pellagatti A; Nanda K; Giese T; Germing U; Baldus S; Boultwood J; Ho AD; Dreger P; Luft T
    Int J Cancer; 2016 Sep; 139(6):1402-13. PubMed ID: 27170453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
    Kantarjian H; Oki Y; Garcia-Manero G; Huang X; O'Brien S; Cortes J; Faderl S; Bueso-Ramos C; Ravandi F; Estrov Z; Ferrajoli A; Wierda W; Shan J; Davis J; Giles F; Saba HI; Issa JP
    Blood; 2007 Jan; 109(1):52-7. PubMed ID: 16882708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
    Kantarjian H; Beran M; Cortes J; O'Brien S; Giles F; Pierce S; Shan J; Plunkett W; Keating M; Estey E
    Cancer; 2006 Mar; 106(5):1099-109. PubMed ID: 16435387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.